Medvantx Adds Chief Technology Officer to its Senior Management Team

Medvantx Adds Chief Technology Officer to its Senior Management Team

SAN DIEGO, Tuesday, January 07, 2020 –Medvantx, Inc., the leading provider of ecommerce and final mile delivery solutions, announces that Jeremy (“Jerry”) V. Gross has joined the company as Chief Technology Officer (CTO). This newly created position will focus on the further development of the company’s proprietary ecommerce, pharmacy and final mile delivery platform.

“Jerry’s unique combination of expertise from the financial technology sector pharmaceutical and logistics industries, is a key addition to Medvantx, and will help our customers navigate a rapidly changing healthcare marketplace,” said Robert J Feeney, Jr., founder and CEO of Medvantx.

Gross brings a 30+ year track record of leading development teams and leveraging emerging technologies to create disruptive innovation within biopharma, healthcare and the financial technology industries. Previously, he held senior technology, innovation and incubation leadership roles at Amgen, McKesson, Intuit and JPMorgan. Gross has lead the design, development and commercialization of e-commerce, complex back-end logistics systems and cloud-based data solutions for pharmaceutical and global distribution companies, as well as early online banking and e-Commerce platforms in financial services.

“Medvantx is one of the early pioneers in the direct-to-patient space and has the experience and infrastructure necessary to support large scale digital transformation strategies for pharmaceutical companies,” said Jerry Gross, chief technology officer at Medvantx. “I’m thrilled to join the Medvantx team, and to work with leading developers and technology partners to identify and pilot emerging technologies in consumer engagement, machine learning and big data to bring advances to the healthcare industry.”

As CTO, Gross will lead Medvantx newly created business unit dedicated to advancing the company’s technology platform, and identify new technology-based solutions for the company’s clients. This business unit will be located in San Diego to encourage collaboration with the local digital healthcare and technology community.

About Medvantx, Inc.

Medvantx, Inc., partners with pharmaceutical and biopharmaceutical companies to bring medicines to patients with a direct-to patient platform that streamlines delivery, minimizes cost and enhances the patient experience. Managing the entire process from end to end, Medvantx offers e-commerce solutions, pharmacy services and innovative final-mile fulfillment. Licensed in all 50 states and handling more than $7.5 billion in prescriptions annually, Medvantx has been redefining pharmacy for over 15 years.

Media contact:

Anne King
(212)779-8975
anne.king@kingpr.net

Medvantx contact:

Bobbie Montgomery
(610)740-4879
bobbie@montgomery@medvantx.com

Source:
Medvantx, Inc.

Related Links:
www.medvantx.com

To Adjudicate or Not to Adjudicate?

To Adjudicate or Not to Adjudicate?

More and more these days, brand pharmaceutical companies run up against a roadblock when trying to obtain reimbursement from third-party payors, pharmacy benefit managers (PBMs), and insurance carriers. The roadblock? The drug exclusion list.

With drug exclusionary lists, payors and PBMs actively block all reimbursement to specific brand drugs at the National Drug Code (NDC) level. If, for some reason, your brand is unfortunate enough to find itself on one of these industry blacklists, tried and true traditional marketing strategies won’t help. To put it bluntly, you’re in trouble.

When it comes to NDC blocks “to adjudicate or not to adjudicate” is no longer the question. The very question itself is taken off the table. When faced with the prospect of a drug exclusion list, pharmaceutical manufacturers have little choice but to take their proverbial medicine.

A History of Adjudication

It wasn’t always like this. In the early days of managed care—some 40 years ago—pharmacy claims were processed on a manual basis. Each insurance company had their own paper claim form and pharmacies were required to complete and submit the forms for reimbursement in what was called a “shoebox.” It wasn’t uncommon for patients to collect and submit dozens of manual paper claims at once. At the time, there was no prescription medication drug benefit, as medications weren’t covered by insurance the way they are today.

In 1976, the National Council for Prescription Drug Programs (NCPDP) was formed to standardize third-party claim forms and ease the burden on pharmacies and consumers. The result was the Universal Claim Form, eventually adopted by most third-party payers.

Over the next 15 years, significant advances in technology made possible real-time information on eligibility, maximum amount dispensed, drug interactions, drug utilization, copay amount, and claim submission for payment. These advances opened the door for computerized point-of-sale (POS) systems that automated the entire pharmacy claims process.

Every U.S. pharmacy, whether retail, specialty, or mail-order, eventually had a proprietary or commercial pharmacy software system to adjudicate third-party pharmacy claims using the NCPDP standard.

The Rise of the PBM

Enter PBMs, which formed to help large insurance carriers and self-insured employers manage their pharmacy benefits and claims. In the early days of managed care, adjudication was a straightforward process. That’s because the majority of brand drugs were in one of three formulary tiers. Each tier presented a unique set of challenges. Tier 2 usually required a very aggressive rebate strategy, while Tier 3 required an expensive copay offset strategy.

In order to negotiate lower discounts and implement generic maximum allowable cost (MAC) lists, PBMs created their own retail pharmacy networks and, eventually, mail-order and specialty pharmacies as well. Increasingly exclusive formulary lists allowed them to negotiate rebate contracts with pharmaceutical companies, and it wasn’t long before PBMs were generating revenue on every stage of the pharmacy and pharmacy claim process.

These processes have resulted in PBMs becoming some of the largest and most profitable corporations in the world. Recently, there has been unprecedented consolidation within the industry, as PBMs have merged with national retailers and insurance carriers, further solidifying their stranglehold on the market. This vertical integration of the pharmacy supply chain has created winners and losers within the brand drug marketplace.

Hit and Miss Attempts to Counter PBM Controls

Over the past five years, many pharmacies and drug manufacturers have tried to develop strategies, programs, or techniques to circumvent PBM contracts and controls. Unfortunately, few of these attempts have been sustainable or scalable, and most have failed.

The most common strategy has been to create a “network” of individual retail pharmacies across a broad geography to adjudicate brand drug claims and then mail them directly to patients. This is only an effective strategy for very low-volume and/or low-cost medications, though.

The problem is, as soon as the program scales and becomes successful, PBMs notice that large numbers of claims are being processed outside the geographical location of a retail pharmacy service area. At that point, the PBM will notify the retail pharmacy that it is in breach of its retail contract and the pharmacy is forced to stop its participation in the program immediately.

If a retail pharmacy loses one of the top three PBM contacts, it can be devastating to their business. Over the years, the industry has seen numerous pharmaceutical companies buying or using small independent pharmacies across the country to stay one step ahead of PBMs. This business model is ultimately a whack-a-mole strategy, lacking both long-term sustainability and scalability.

The industry has also seen large national retail pharmacies create direct channels to consumers that bypass the traditional PBM model. But even this strategy has not been broadly adopted nor effective. Often the channel conflicts with state Boards of Pharmacies’ mandates that generic drugs not be dispensed without a dispense as written (DAW) code submitted by the physician. Obstacles like these ultimately make these strategies too challenging for any national retail pharmacy chain to successfully implement and execute.

The State of the Industry Today

Little has changed since the emergence of PBMs. Brand manufacturers are still faced with limited options and are losing ground with third-party payors, who are increasingly trying to limit consumer choice and interfere in the physician-patient relationship.

Given all the complexities and past failures, it sometimes seems like the best option is to continue within traditional channels and develop ways to compete for a smaller share of an increasingly smaller pie.

There are bright spots on the horizon, though.

Over the past few years, the industry has seen successes as brand manufacturers move to consumer-facing, direct-to-patient (DTP) models.

For Manufacturers, the Future is Direct

Loss of exclusivity (LOE), lifestyle, and dermatology products have all seen the potential of e-commerce driven direct-to-patient channels. These programs have been a boon for manufacturers faced with high distribution costs, even higher retail switching rates, prescription abandonment, and a low rate of insurance coverage.

The value of direct-to-patient channels lies in their flexibility and customization. Each manufacturer and each product are unique; they each have their own strengths and weaknesses that can be leveraged or addressed by a dedicated direct-to-patient channel. Innovative final mile solutions round out an integrated platform of services that improve patient experience from the moment they order their prescription to the moment they receive it at home.

Best of all, there are more options available now than ever before, as the onset of telemedicine, e-commerce, and modified hub services make the next generation of pharmacy services a brighter future for pharmaceutical manufacturers.

Schedule your Direct-to-Patient consultation today

Reach Patients Faster

Our direct-to-patient platform collapses the supply chain and brings manufacturers closer to patients. Contact us today to see how we can help you reach patients faster.

TALK TO AN EXPERT

About Us

At Medvantx, we give pharmaceutical brands a better way to connect with patients who need them: directly and immediately.That’s how we’re Redefining Pharmacy.

LEARN MORE

The Definitive Guide to Direct-to-Patient

Everything pharmaceutical manufacturers need to know about direct-to-patient channels.

Manufacturers in the New Age of Online Pharmacy

Manufacturers in the New Age of Online Pharmacy

As the late great Yogi Berra once said, “It’s déjà vu all over again.” It seems the age of the digital pharmacy is here (again). An internet search for “Roman” history is now more likely to return results for erectile dysfunction. And it seems like a new player enters the marketplace every day.

A number of these companies are breathing new life into multi-source generics by rebranding them under their own name. Some are founded on telemedicine services that preclude patients having to travel to a prescribing physician. Still others are focused on specific disease states or essentially digital versions of the traditional pharmacy experience.

The question is, other than the passage of time, has anything really changed since the Drugstore.com implosion? After all, PBMs still block these pharmacies from seeking reimbursement. One has to question the long-term financial viability of the massive direct-to-consumer campaigns these companies are deploying to acquire patients given generic drug margins in the era of $4 generics at Walmart.

Whether we’re seeing the early days of a new market or tech-savvy entrepreneurs making the same mistakes of the dot-com bubble, the upshot of all of this activity is an increasingly disorganized competitive landscape and thoroughly confused consumer base.

Customers don’t yet understand the differences among online pharmacy brands and that confusion is likely to grow, as dozens of companies get in on the action. This includes legacy brands like CVS partnering with InstaCart on same-day delivery or the most momentous harbinger of the age of online pharmacy: Amazon’s acquisition of PillPack.

Pharmaceutical manufactures risk ceding their brand franchises to private label generics powered by digital pharmacy platforms.

For pharmaceutical manufacturers, the new age of online pharmacy represents both an imminent threat and a new commercial opportunity. Not only will brand manufacturers have to continue to contend with traditional generics post-LOE, they now find themselves competing against rebranded generics, complete with slick private equity backed marketing campaigns, seamless digital experiences, and custom-branded packaging. (As if the ever-growing expansion of formulary exclusion lists weren’t enough.)

If manufacturers who have invested an average $2.6 billion in the development of a brand franchise want to avoid ceding their brands to these new digital upstarts, they are going to have to rethink not only the way they manage their LOE strategies, but also develop new e-commerce platforms to engage and retain consumers and streamline the final-mile delivery of medications into the hands of the patients who need them.

Frictionless Digital Commerce

Consumers today expect a frictionless digital commerce experience. Gone are the days of waiting three weeks for a doctor’s appointment, getting a prescription in person, driving to the pharmacy, finding parking, waiting in line, and filling that prescription before finally driving back home.

As with every other corner of the retail sector, seamless digital experiences are reinventing the way patients purchase and receive medications.

The world’s largest retailer has entered the fray and more and more patients are discovering the burgeoning crop of online pharmacies, each of which feature smartly designed websites with streamlined user experiences. For millennial-aged men, numerous telehealth companies have destigmatized the process and made shopping for ED and hair loss medications almost hip. Others have extended the experience to women’s health, contact lens, and more.

Patient experience in the age of online pharmacy is highly engaging and—in stark contrast to the traditional pharmacy model—even enjoyable. With telemedicine and online chat bots often built into the experience, online pharmacy eliminates the need for doctors’ appointments altogether. The medicine you need can be delivered to your door literally hours after you complete your online order.

End-to-End Customer Experience

From marketing campaigns to personalized packaging, e-commerce offers patients the exact same generic prescriptions they used to get through a complex and inconvenient traditional pharmacy process through a high-end, branded customer experience that is meticulously designed for utmost convenience.

Online pharmacies offer opportunities for users to interact with a customer service representative at any point in the patient journey, delighting customers and maximizing conversion rates.

E-commerce-based online pharmacies provide smart checkout technology with easy payment options to streamline the purchase process. They capitalize on free shipping as a powerful customer motivator. And they design the entire experience for mobile, with the understanding that in the age of online pharmacy the overwhelming majority of consumers are interacting with brands on the go.

  • Customers expect a personalized experience
  • Free shipping is a powerful motivator for customers
  • Customers expect consistency regardless of channel
  • Brands should provide as many options as possible to interact with Customer Service
  • More people are using mobile for price comparisons while shopping
  • Smarter checkout process with easy payment options
  • Growing interest in customized packaging among consumers

The new face of generics in the age of online pharmacy isn’t what it used to be. Homogeneous translucent orange bottles procured through a byzantine and bureaucratic process have been replaced by sleekly packaged branded containers prescribed, purchased and delivered in a matter of hours.

It isn’t just rebranded generics that pharmaceutical manufacturers have to worry about. With acquisition of PillPack and its pharmacy licensure in all 50 U.S. states, Amazon has laid the groundwork for a prescription marketplace that will fundamentally change the brand-name pharmaceutical landscape, as well.

Whether or not manufacturers participate in Amazon’s prescription marketplace and/or outsource fulfillment to the company’s vast and rapidly expanding network of distribution centers, should be a carefully deliberated decision. The algorithm-driven commoditization implicit in the arrangement would likely have a significant impact on a manufacturer’s brand equity and long-term market strategy.

Pharmaceutical Manufacturers in the Age of Online Pharmacy

What happens when the consumer is trained to think about the pharmacy brand and not the medication? Online pharmacy represents a real threat to manufacturers, but within that threat exists an opportunity. Manufacturers, after all, have one thing that the new crop of fly-by-night online pharmacies don’t have: brand equity.

Manufacturer brand equity and loyalty established with physicians and consumers over a product’s 17-year proprietary lifecycle can be retained and even enhanced by engaging customers directly in the frictionless digital commerce model they have come to expect, complete with end-to-end customer experience.

In the age of digital pharmacy, manufacturers need a direct-to-patient platform powered by e-commerce technology, anticipatory logistics, and innovative final-mile solutions. They need to provide patients with an alternative to the fragmented and overly complex traditional pharmacy process that prevents nearly a third of all new prescriptions for patients with chronic diseases from being filled.

In this new world, manufacturers need an independent way to leverage customer loyalty, compete against the rise of these rebranded generics, and avoid the commoditization implicit in the forthcoming Amazon prescription marketplace.

E-commerce and the age of the online pharmacy stands to represent either the most lucrative opportunity in the history of the industry or an existential threat to the brand equity that manufacturers have built over decades of being in business.

Schedule your Direct-to-Patient consultation today

Reach Patients Faster

Our direct-to-patient platform collapses the supply chain and brings manufacturers closer to patients. Contact us today to see how we can help you reach patients faster.

TALK TO AN EXPERT

About Us

At Medvantx, we give pharmaceutical brands a better way to connect with patients who need them: directly and immediately.That’s how we’re Redefining Pharmacy.

LEARN MORE

The Definitive Guide to Direct-to-Patient

Everything pharmaceutical manufacturers need to know about direct-to-patient channels.

The Formulary Exclusion Squeeze

The Formulary Exclusion Squeeze

With the advent of managed care in the 1980s came prescription formularies—lists of medications that were approved for prescription to patients in various care settings.

Originally, formulary inclusion was based on third-party assessment and clinical evaluation of the efficacy, safety, and cost-effectiveness of a given medication. These lists represented a sensible way for payors, providers and patients to determine which drugs qualified for coverage and optimized the cost vs. clinical effectiveness equation.

Over the past thirty years, however, formularies have evolved from straightforward, single-tier lists of brand and generic medications to become exceedingly complex matrices of as many as ten separate tiers with selection criteria than can be described as opaque at best.

What was once defined by objective clinical standards is now dictated by for-profit middlemen in the form of pharmacy benefit managers (PBMs).

The growth of tier-based differential rebates—created by PBMs as a means for pharmaceutical manufacturers to secure access to formularies—fundamentally altered the role of formularies and become the driving force of formulary inclusion.

As the prevalence and size of these rebates has grown, formularies have become increasingly narrow, evolving from inclusion lists to the exclusion lists we know today. The result is that patients now pay larger and larger percentages of the cost of certain necessary medications, sometimes as much as 100 percent.

The Blacklists of the Pharmaceutical Industry

Formulary exclusion lists have become the blacklists of the pharmaceutical industry, created by PBMs to block consumers from gaining access to medications, not because of efficacy or safety concerns, but solely as leverage points for PBMs in their rebate negotiations with manufacturers.

And the exclusivity of formulary lists only continues to grow.

The size of formulary exclusion lists has increased by nearly 160 percent since 2014, during which time the combined number of treatments on CVS Pharmacy’s and Express Scripts’ drug formulary exclusion lists grew from 132 to 344.

Over this same period, the prevalence of consumer-driven health insurance models also grew substantially; approximately 40 percent of consumers are now enrolled in some form of high-deductible health plan.

With patients taking on more and more responsibility for the management of their own healthcare and experiencing first-dollar exposure for the actual costs of prescription medications, should a PBM continue to decide which medications prescribers and their patients select as optimal for their care?

When PBMs make these decisions based in large part on the scope and depth of the rebates that manufacturers are willing to pay, the resultant limitations on patient choice seem especially cynical.

How did we get to a point where one healthcare company can pay another to block patient access to a competing product in the marketplace?

An Existential Threat to Manufacturers

Given the recent vertical integration trifecta of Aetna/CVS (a payor/retailer combination), Cigna/ESI (a payor/PBM combination) and Walgreens/AmeriSource Bergen (a retail/wholesale combination), now is a good time to think about the next logical step in the evolution of increasingly narrow formularies.

If the PBM and the retailer are the same company, what motivation would they have to even stock non-formulary drugs in their stores? If wholesalers can’t get them into stores, why should they even include such medications in their supply chain or distribution networks?

CVS and Walgreens comprise no less than a 40-percent share of the US retail pharmacy marketplace. The manufacturers of products excluded from these companies’ formularies face an existential threat when it comes to medications in which they’ve invested billions of dollars to research, develop, and commercialize.

Overnight, the average $2.6 billion that manufacturers invest in the development of a brand franchise could be all but wiped out by a large PBM/retailer partnership that decides not to stock their product.

The upward trend of mergers and acquisitions throughout the healthcare industry means that the scenario described above isn’t just pessimistic speculation. It’s only a matter of time before patient access to medication via traditional retail channels is defined by singular corporate entities who control both the playing field and the rules of the game. And that’s just brick-and-mortar retail.

With its acquisition of mail-order pharmacy PillPack, Amazon’s entry into the pharmacy space represents a consolidated corporate force majeure on the online flank of the competitive landscape as well.

Leveraging Brand Loyalty with Direct-to-Patient

To survive in this new industry paradigm, pharmaceutical manufacturers are going to have to take their fate into their own hands.

Only by establishing independent, direct-to-patient channels can manufacturers ensure that the massive investments they’ve made and continue to make into innovation and development won’t be subject to the whims of PBMs and retailers who deem their products cost prohibitive.

By utilizing direct-to-patient platforms driven by e-commerce and anticipatory logistics, manufacturers will always have an ace up their sleeve when it comes to patient access, engagement and retention. Brand loyalty, after all, is a powerful thing.

Manufacturers can leverage brand loyalty by engaging patients on the clinical value of their brand and offering a more consumer-friendly alternative to the fragmented and overly complex traditional pharmacy process—an alternative that is streamlined by e-commerce and anticipatory logistics complete with innovative final-mile solutions.

The reality is that today’s formulary lists are pay to play, and rebates are the cost of admission. But increasingly narrow formularies are just the tip of the iceberg when it comes to the challenges that pharmaceutical manufacturers will face in the years ahead.

Brands that approach these challenges with passive strategies dependent on traditional channels risk facing existential threats to core products. Manufacturers that tackle these challenges head on, with independent, direct-to-patient platforms at the ready, will be poised to define the future of the industry themselves, rather than letting it define them.

Schedule your Direct-to-Patient consultation now

Reach Patients Faster

Our direct-to-patient platform collapses the supply chain and brings manufacturers closer to patients. Contact us today to see how we can help you reach patients faster.

TALK TO AN EXPERT

About Us

At Medvantx, we give pharmaceutical brands a better way to connect with patients who need them: directly and immediately.That’s how we’re Redefining Pharmacy.

LEARN MORE

The Definitive Guide to Direct-to-Patient

Everything pharmaceutical manufacturers need to know about direct-to-patient channels.

The Future of Final-Mile Pharmacy

The Future of Final-Mile Pharmacy

The way consumers purchase goods and services is changing by the minute. Anticipatory logistics, final-mile transportation networks, and same-day delivery services are fundamentally shifting how consumers access goods and services. New technologies and supply chain models that combine the convenience of e-commerce with the immediacy of traditional brick-and-mortar stores are the direct descendants of the biggest influencer in recent retail history: Amazon. With its rapid delivery service model, Amazon has transformed the retail landscape, along with customer expectations, establishing an aggressive benchmark of near frictionless consumer experience in virtually every industry.

To accommodate growing consumer demand for instantaneous order fulfillment, an ever-expanding array of well-financed final-mile platforms like Uber, Postmates, and Deliv have entered the fray, investing billions of dollars in the race to create crowd-sourced and asset-light regional logistics networks. These networks are designed to support the scale economies required to provide same-day delivery service in urbanized areas with dense metropolitan populations. As the new retail model expands to healthcare, it’s really only a matter of time before companies that provide car service and food delivery are playing an integral role in the distribution of pharmaceuticals as well.

  • 61% of internet users would pay more for same-day delivery
  • 82% of shoppers want same-day shipping options
  • 64% of millennials are more likely to purchase online if same-day is an option
  • 25% of shoppers would abandon their cart if same-day delivery was unavailable

A Supply Chain Ill-Equipped for the Future

The basic schematic of the pharmaceutical supply chain in the United States dates back to the turn of the century. Because it is inherently retrospective in nature, it is fundamentally ill-equipped to support the requirements of e-commerce platforms, including anticipatory logistics, distributed networks and home delivery. Industry pundits are quick to point out that prescription medications aren’t the same as books. And they’re right. The book industry doesn’t have to contend with the impact of entrenched middlemen, a crisis of runaway costs, poor product quality, and low consumer expectations. Would the book industry tolerate a supply chain where up to 37 percent of customer orders were never even filled?

Studies have shown that fully a third of all new prescriptions written by physicians for the treatment of patients with chronic disease are never filled. Research into the cause shows that much of the abandonment rate can be attributed to the byzantine complexity and inconvenience of today’s pharmacy process. While the complex supply chain requirements for prescription drugs differ from those for consumer packaged goods, Amazon’s entry into the pharmaceutical marketplace likely means the pharma industry is going to have to adapt to modern e-commerce models—not the other way around.

A Game Plan for the Amazon Effect

As consumer behavior continues to change, pharmaceutical manufacturers can expect competitors to respond with new fulfillment channels to meet increased customer expectations. Pharmacy Fulfillment by Amazon (PFBA) and its existing network of 150 distribution centers across the country will drive a paradigmatic industry shift in the coming years. Manufacturers need a game plan if they hope to survive the infamous “Amazon effect.”

What should that game plan look like? For starters, it needs a final-mile strategy. One option to consider for that strategy will be Amazon itself. For a defined set of service fees (as opposed to rebates and the traditional AWP, WAC and AMP gamesmanship), manufacturers will be able to advertise their brands on Amazon as well as have their products fulfilled by the company’s vast and rapidly expanding network of distribution centers. Whether or not to participate in Amazon’s prescription marketplace and/or outsource fulfillment to the company should be a carefully deliberated decision as the volume and commoditization entailed by the partnership would have a significant impact on a manufacturer’s brand and longer-term strategy.

An alternative to Amazon for pharmaceutical companies could be to partner with existing logistics companies like UPS, FedEx, or other third-party courier services to offer home delivery and position their product in regional distributions centers closer to consumers in population-dense geographic markets. The problem is that these companies don’t have the required licensure, pharmacy operations, dispensing automation, or expertise necessary to manage and dispense prescriptions to consumers at home.

An Independent, Direct-to-Patient Alternative

For manufacturers, the best alternative to partnering with Amazon is an independent solution, one that moves the traditional logistics and pharmacy process upstream in the value chain, closer to the end consumer. From e-commerce to pharmacy to final-mile fulfillment services, the best alternative to Amazon is a direct-to-patient platform that gives manufacturers faster, more efficient ways to reach patients. This anticipatory e-commerce pharmacy channel forms the backbone of the Medvantx platform.

With the industry’s only end-of-runway pharmacy, Medvantx is enabling manufacturers to reach patients anywhere in just hours. Partnering with UPS, we offer the largest dedicated healthcare storage and logistics capabilities in the U.S. Our proprietary final-mile solution and comprehensive fulfillment capabilities are designed to collapse the supply chain and bring manufacturers closer to patients.

Final-mile delivery is set to become a critical competitive battleground for the pharmaceutical industry in the coming age of e-commerce and instant fulfillment. To ensure the independence and long-term viability of their brands, especially in the face of increased formulary exclusion, manufacturers need to establish a final-mile strategy that will be able to keep pace with the evolution of consumer demand in the years ahead.

Schedule your Direct-to-Patient consultation today

Reach Patients Faster

Our direct-to-patient platform collapses the supply chain and brings manufacturers closer to patients. Contact us today to see how we can help you reach patients faster.

TALK TO AN EXPERT

About Us

At Medvantx, we give pharmaceutical brands a better way to connect with patients who need them: directly and immediately.That’s how we’re Redefining Pharmacy.

LEARN MORE

The Definitive Guide to Direct-to-Patient

Everything pharmaceutical manufacturers need to know about direct-to-patient channels.

The Amazon Pharma Threat

The Amazon Pharma Threat

Amazon has entered the pharmacy business.

After years of increasing speculation, the company finally made it official by acquiring PillPack, a relatively new niche player in the mail-order and adherence packaging space, for a reported $1 billion in June of 2019. With the purchase, Amazon has acquired pharmacy licenses in all 50 U.S. states.

While the company was already actively supplying products to hospitals and healthcare facilities and recently announced a partnership with Berkshire Hathaway and JP Morgan Chase to manage employee healthcare costs, Amazon’s acquisition of PillPack suggests it has its sights set on becoming a significant player in the half-a-trillion-dollar U.S. pharmaceutical industry.

What does Amazon’s entry into the pharmacy space mean for pharmaceutical manufacturers and traditional supply and value chain providers?

If its approach to other industries is any indication, Amazon will change the way consumers access pharmacy care and collapse the supply chain in the future.

The question for manufacturers and the industry at large is, what now? Embrace Amazon? Or build, buy or partner to develop an e-commerce-based direct-to-patient platform of their own?

  • With PillPack, Amazon has acquired pharmacy licenses in 49 states
  • 85% of Amazon Prime’s 100M members say they’d buy drugs from Amazon
  • Inefficiencies & rebates currently consume $94/brand drug
  • HHS Secretary Azar has threatened to eliminate rebates entirely
  • Amazon’s access to consumer data will redefine marketing & retail
  • The Prime algorithm could replace PBMs & retailers altogether

Consolidate or Innovate?

Amazon’s impact on the pharmaceutical industry was nearly instantaneous, as wholesalers, distributers, PBMs, insurers, and retailers lost over $20 billion in market capitalization on the day of the announcement.

As has typically been the case in industries “disrupted” by Amazon, many of the legacy players in the pharmacy value chain decided to consolidate rather than innovate in the face of the news. Anxiety over Amazon’s entry was widely assumed to be a contributing factor in CVS Health’s bid to buy Aetna and Cigna’s shareholders voting to support its pending acquisition of Express Scripts, just to name a few.

This recent spate of mega-mergers of wholesalers, retailers, PBMs and payors was a predictable reaction, but does little to actually solve the challenges presented by Amazon’s entry. Mergers and acquisitions do nothing to create new, sustainable competitive advantages; they merely double down on existing market forces.

Companies that have withstood the Amazon threat in other industries are those that have turned to innovation, not consolidation, as a strategy.

The Amazon Effect: Prescription Medications

Changes to prescription medication formularies have been well underway for years, as varying levels of co-pay tiers continue to evolve into exclusion lists. Drug formulary exclusion lists have increased by nearly 160 percent since 2014, according to a recent Doctor-Patient Rights Partnership report. In 2014, there were 132 treatments on CVS Pharmacy’s and Express Scripts’ combined drug formulary exclusion lists. In 2018, that number has grown to 344.

As a result, pharmaceutical manufacturers can no longer rely on payor and PBM rebate strategies to create access to, or a more level playing field for, their products. As part of the Trump administration’s plan to lower prescription medicine costs, U.S. Health and Human Services Secretary Alex Azar recently stated that it was within his agency’s power to actually eliminate rebates on prescription drug purchases altogether.

With rebates threatened, pharmacy retailers owned or controlled by payors can be expected to take formulary exclusion to its logical conclusion—no longer even stocking non-formulary products in their pharmacies. The impact of this change would ripple backward up the supply chain, and manufacturers could find themselves without access to any large U.S. channels of distribution for their products.

While legacy providers battle it out for an increasingly smaller piece of the pie, Amazon could replace the concept of formularies, tiers, and rebates all together with its Prime software algorithm, favoring generic conversion over branded medications.

Pharmaceutical companies that have invested billions of dollars into drug discovery and branding would find themselves commoditized as consumers look to Amazon for their medications along with everything else. Check-out baskets would begin to fill with private label Amazon Prime brand of generic pharmaceuticals.

The Amazon Effect: A New Retail Model

Amazon’s impact on traditional brick-and-mortal channels is well known: the Amazon Effect. The Amazon Effect has led consumers to expect an almost completely frictionless shopping experience with near-immediate results.

Traditional retail stores and independent pharmacies are already rapidly disappearing, replaced by large chain drug stores as payor pharmacy networks become increasingly narrow and restrictive. Aetna members, for example, might soon only be allowed to purchase medications from CVS stores.

With its massive marketplace business model and use of e-commerce vs brick-and-mortar, Amazon has demonstrated a unique ability to drive manufactures into fully commoditized marketplaces and to reach consumers upstream in the value chain.

Amazon’s ability to collect information about patients will further forever change the prescription medication marketing mix. The company could use data, for instance, to target ads for self-help books at patients filling prescriptions for anti-depressants.

With its Whole Foods locations and Alexa voice command system, Amazon has a multifaceted arsenal to upsell pharmacy customers and cross-promote products. In his annual letter to shareholders, Amazon CEO Jeff Bezos recently revealed the company has more than 100 million Prime members. And according to a recent study, the vast majority of Prime members who also have health insurance said they would be willing to purchase prescription drugs from Amazon online.

No fewer than 85 percent of insured Prime members told Deutsche Bank they would be comfortable buying drugs straight from Amazon.com.

With the recent PillPack acquisition, Amazon now also has the pharmacy licensure and infrastructure to begin to disrupt the cash-pay prescription business. Prescriptions purchased by the uninsured and underinsured population represent an invaluable opportunity for competitive pricing in each of the 49 U.S. states where Amazon now has a license to ship medications.

The traditional distinctions between prescription assistance, free trial, and direct-to-patient programs will only continue to blur as consumer engagement platforms shift from traditional to more e-commerce enabled approaches.

A System Ripe for Change

Apart from the mergers and acquisitions in the value chain, many have viewed Amazon’s entry into the pharmacy industry with only tempered concern. Certainly, Amazon represents a theoretical threat to the industry status quo, but immovable forces like market share consolidation among major PBMs will mean the company’s growth will be kept in check.

Healthcare is complex and different. Right?

The reality is that seemingly immovable forces have never stopped Amazon in the past. The company has a history of starting small in the industries it enters, testing the market and fine-tuning its services, before launching full-fledged commercial operations.

Kaiser Health News found that redundancies, inefficiencies and rebates in the pharmacy supply chain consume approximately 31 percent or up to $94 within the average branded medication.

In the past, Amazon has disrupted vertical industries where the margin compression opportunities were measured in basis points, not hundreds of dollars per order. The question isn’t whether they will be successful in healthcare, but why buy a niche start up vs larger platform? And what took them so long?

Its puzzling entry strategy does not preclude Amazon from someday leveraging its unparalleled brand loyalty and massive e-commerce infrastructure to cut out PBMs and retailers altogether and simply sell product online for cash. Why fight against an entrenched, antiquated system when you can just build your own?

As rebates no longer work—or disappear altogether—and chain drug continues to narrow, the system is increasingly ripe for change.

The Road Ahead

While it is certainly the most widely publicized, Amazon’s entry into the healthcare and pharmacy marketplace is really just the latest development in the rapidly changing landscape of the pharmaceutical industry. Changing industry fundamentals have been driven by the shift to a more consumer centric model, and that trend is certainly only going to accelerate.

If manufacturers are commoditized by an algorithm-driven e-commerce model, they can expect to be forced into reverse auctions to compete exclusively on price in a race to the bottom (also known as the Amazon Marketplace).

As it has shown in nearly every industry it has entered, Amazon’s platform is unique in that brands either use it or they die. Like many retail brands before them, pharmaceutical manufacturers risk losing their independence in the new Amazon pharmacy marketplace model as they lose control of their brands.

As they look toward the future, manufacturers will need new and independent direct-to-patient platforms powered by e-commerce technology, anticipatory logistics, and innovative final-mile solutions if they are to survive in this new industry paradigm. They will need ways to move the pharmacy process upstream in the value chain so that it is as close to the consumer as possible.

In the new era of pharmacy, manufacturers will need a solution to the fragmented and overly complex pharmacy process that is fully automated and streamlined by e-commerce technology, so that what is now measured in days can be measured in mere hours.

What manufacturers need is independent, integrated direct-to-patient solutions.

Schedule your Direct-to-Patient consultation now

Reach Patients Faster

Our direct-to-patient platform collapses the supply chain and brings manufacturers closer to patients. Contact us today to see how we can help you reach patients faster.

TALK TO AN EXPERT

About Us

At Medvantx, we give pharmaceutical brands a better way to connect with patients who need them: directly and immediately.That’s how we’re Redefining Pharmacy.

LEARN MORE

The Definitive Guide to Direct-to-Patient

Everything pharmaceutical manufacturers need to know about direct-to-patient channels.